WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ:330350)
South Korea
· Delayed Price · Currency is KRW 5,960.00
-130.00 (-2.13%)
At close: Mar 28, 2025, 3:30 PM KST
KOSDAQ:330350 Revenue
In the year 2024, WITHUS PHARMACEUTICAL Co.,LTD. had annual revenue of 102.72B KRW with 28.21% growth. WITHUS PHARMACEUTICAL Co.,LTD. had revenue of 22.84B in the quarter ending December 31, 2024, a decrease of -11.67%.
Revenue
102.72B
Revenue Growth
+28.21%
P/S Ratio
0.78
Revenue / Employee
848.94M
Employees
121
Market Cap
80.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 102.72B | 22.60B | 28.21% |
| Dec 31, 2023 | 80.12B | 15.44B | 23.87% |
| Dec 31, 2022 | 64.68B | 7.26B | 12.65% |
| Dec 31, 2021 | 57.42B | 4.01B | 7.51% |
| Dec 31, 2020 | 53.41B | 1.01B | 1.93% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Electronics | 300.87T |
| SK hynix | 66.19T |
| LG Energy Solution | 25.62T |
| Samsung Biologics | 4,547.32B |
| Hyundai Motor Company | 175.23T |
| Celltrion | 3,557.30B |
| Kia Corporation | 107.45T |
| KB Financial Group | 15.01T |